JH
James Healy
Director
James HealyDirector
James Healy insider trades: Rapport Therapeutics (RAPP) stock buys and sales
Director, Rapport Therapeutics Last trade Oct 28, 2026 190 Form 4 filings
$0
Sold, last 12 months
0 sales
$20.4M
Bought, last 12 months
4 buys
94
Open-market trades
since 2006
39
Companies
last trade 2026
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
RAPPRapport Therapeutics
Director · last filing Oct 30, 2026
+$30.9M
SPTXSeaport Therapeutics
Insider · last filing May 4, 2026
No market trades
BIOABioAge Labs
Insider · last filing Jun 12, 2026
+$12.0M
AVBPArriVent Biopharma
Director · last filing Jan 31, 2024
+$8.0M
NTRANatera
Insider · last filing Apr 29, 2025
-$37.9M
+$15.7M
VERAVera Therapeutics
10% Owner · last filing Feb 8, 2023
+$14.0M
and 33 more companies
Open-market buys and sales
94 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | RAPP | ↑ Buy | 952,380 | $21.00 | $20.0M | By Sofinnova Venture Partners XI, L.P. | Oct 30, 2026 (2d) |
| Oct 28, 2026 | RAPP | ↑ Buy | 6,933 | $21.00 | $146K | By SummitTX Pinnacle Master, L.P. - Heal | Oct 30, 2026 (2d) |
| Oct 28, 2026 | RAPP | ↑ Buy | 6,395 | $21.00 | $134K | By SummitTX Master, SPC -SummitTX Apex S | Oct 30, 2026 (2d) |
| Oct 28, 2026 | RAPP | ↑ Buy | 3,772 | $21.00 | $79K | By SummitTX Master, SPC - SummitTX Alpha | Oct 30, 2026 (2d) |
| Sep 27, 2024 | BIOA | ↑ Buy | 588,888 | $18.00 | $10.6M | Sofinnova Venture Partners XI, L.P. | Sep 27, 2024 (0d) |
| Sep 27, 2024 | BIOA | ↑ Buy | 26,497 | $18.00 | $477K | Crestline Summit Pinnacle Master, L.P. | Sep 27, 2024 (0d) |
| Sep 27, 2024 | BIOA | ↑ Buy | 21,814 | $18.00 | $393K | Crestline Summit Master, SPC - PEAK SP | Sep 27, 2024 (0d) |
| Sep 27, 2024 | BIOA | ↑ Buy | 18,353 | $18.00 | $330K | Crestline Summit Master, Spc - Crestline | Sep 27, 2024 (0d) |
| Sep 27, 2024 | BIOA | ↑ Buy | 11,113 | $18.00 | $200K | Sofinnova Synergy Master Fund LP | Sep 27, 2024 (0d) |
| Jul 1, 2024 | RAPP | ↑ Buy | 15,253 | $24.52 | $374K | By Crestline Summit Master, SPC - CRESTL | Jul 3, 2024 (2d) |
| Jul 1, 2024 | RAPP | ↑ Buy | 14,573 | $24.52 | $357K | By Crestline Summit Master, SPC - PEAK S | Jul 3, 2024 (2d) |
| Jul 1, 2024 | RAPP | ↑ Buy | 14,206 | $24.52 | $348K | By CRESTLINE SUMMIT PINNACLE MASTER, L.P | Jul 3, 2024 (2d) |
| Jun 10, 2024 | RAPP | ↑ Buy | 470,589 | $17.00 | $8.0M | By Sofinnova Venture Partners XI, L.P. | Jun 10, 2024 (0d) |
| Jun 10, 2024 | RAPP | ↑ Buy | 26,278 | $17.00 | $447K | By Crestline Summit Master, SPC - PEAK S | Jun 10, 2024 (0d) |
| Jun 10, 2024 | RAPP | ↑ Buy | 25,455 | $17.00 | $433K | By CRESTLINE SUMMIT PINNACLE MASTER, L.P | Jun 10, 2024 (0d) |
| Jun 10, 2024 | RAPP | ↑ Buy | 18,641 | $17.00 | $317K | By Sofinnova Synergy Master Fund LP | Jun 10, 2024 (0d) |
| Jun 10, 2024 | RAPP | ↑ Buy | 17,861 | $17.00 | $304K | By Crestline Summit Master, SPC - CRESTL | Jun 10, 2024 (0d) |
| Jan 30, 2024 | AVBP | ↑ Buy | 444,444 | $18.00 | $8.0M | Sofinnova Venture Partners XI, L.P. | Jan 31, 2024 (1d) |
| Dec 13, 2023 | NTRA | ↓ Sell | 644,000 | $58.75 | $37.8M | by Sofinnova Management VIII, L.L.C. | Dec 22, 2023 (9d) |
| Feb 6, 2023 | VERA | ↑ Buy | 285,714 | $7.00 | $2.0M | Direct | Feb 8, 2023 (2d) |
| Jan 13, 2023 | KRTX | ↓ Sell | 6,027 | $199.90 | $1.2M | By Sofinnova Management X, L.P. | Jan 17, 2023 (4d) |
| Nov 28, 2022 | CINC | ↓ Sell | 6,000 | $14.32 | $86K | By Sofinnova Synergy Master Fund, LP | Feb 27, 2023 (91d) |
| Nov 16, 2022 | NTRA | ↓ Sell | 2,400 | $37.71 | $90K | By Sofinnova Synergy Master Fund, LP | Jan 18, 2023 (63d) |
| Aug 11, 2022 | CINC | ↑ Buy | 500,000 | $30.00 | $15.0M | By Sofinnova Venture Partners X, L.P. | Aug 15, 2022 (4d) |
| Aug 11, 2022 | CINC | ↑ Buy | 6,000 | $30.00 | $180K | By Sofinnova Synergy Master Fund, LP | Aug 15, 2022 (4d) |
| Jun 30, 2022 | KRTX | ↑ Buy | 120,000 | $122.80 | $14.7M | By Sofinnova Venture Partners X, LP | Jul 1, 2022 (1d) |
| Apr 1, 2022 | KRTX | ↑ Buy | 47 | $129.38 | $6K | By Sofinnova Synergy Master Fund, LP | Apr 14, 2022 (13d) |
| Feb 10, 2022 | VERA | ↑ Buy | 266,666 | $15.00 | $4.0M | Direct | Feb 14, 2022 (4d) |
| Jan 11, 2022 | CINC | ↑ Buy | 325,000 | $16.00 | $5.2M | By Sofinnova Venture Partners X, L.P. | Jan 13, 2022 (2d) |
| Sep 29, 2021 | CHRS | ↓ Sell | 434,555 | $16.68 | $7.3M | Indirect | Sep 29, 2021 (0d) |
| Jul 22, 2021 | NTRA | ↑ Buy | 2,400 | $113.00 | $271K | By Sofinnova Synergy Master Fund, LP | Jul 26, 2021 (4d) |
| Jul 2, 2021 | KRTX | ↑ Buy | 636 | $117.80 | $75K | By Sofinnova Synergy Master Fund, LP | Jul 7, 2021 (5d) |
| Jul 2, 2021 | AVTE | ↑ Buy | 357,142 | $14.00 | $5.0M | Direct | Jul 6, 2021 (4d) |
| May 18, 2021 | VERA | ↑ Buy | 727,272 | $11.00 | $8.0M | Direct | May 18, 2021 (0d) |
| Feb 9, 2021 | BOLT | ↑ Buy | 450,000 | $20.00 | $9.0M | By Sofinnova Venture Partners X, L.P. | Feb 9, 2021 (0d) |
| Sep 9, 2020 | KRTX | ↑ Buy | 4,557 | $73.75 | $336K | By Sofinnova Venture Partners X, L.P. | Sep 11, 2020 (2d) |
| Sep 8, 2020 | KRTX | ↑ Buy | 62,282 | $71.74 | $4.5M | By Sofinnova Venture Partners X, L.P. | Sep 9, 2020 (1d) |
| Aug 11, 2020 | CMPI | ↑ Buy | 133,333 | $15.00 | $2.0M | Indirect | Aug 12, 2020 (1d) |
| Jul 28, 2020 | INZY | ↑ Buy | 437,500 | $16.00 | $7.0M | Direct | Jul 28, 2020 (0d) |
| Jun 30, 2020 | AKUS | ↑ Buy | 58,823 | $17.00 | $1000K | Direct | Jul 1, 2020 (1d) |
| Jun 2, 2020 | ITRM | ↓ Sell | 500,000 | $1.62 | $812K | Direct | Jun 3, 2020 (1d) |
| Nov 25, 2019 | KRTX | ↑ Buy | 156,250 | $96.00 | $15.0M | By Sofinnova Venture Partners X, L.P. | Nov 25, 2019 (0d) |
| Nov 15, 2019 | NXTC | ↑ Buy | 150,000 | $36.75 | $5.5M | Direct | Nov 19, 2019 (4d) |
| Nov 12, 2019 | GRTX | ↑ Buy | 750,000 | $12.00 | $9.0M | Direct | Nov 12, 2019 (0d) |
| Oct 30, 2019 | YMAB | ↑ Buy | 90,000 | $28.00 | $2.5M | Indirect | Nov 1, 2019 (2d) |
| Jul 2, 2019 | KRTX | ↑ Buy | 700,000 | $16.00 | $11.2M | By Sofinnova Venture Partners X, L.P. | Jul 2, 2019 (0d) |
| Jul 2, 2019 | CHRS | ↓ Sell | 360,000 | $22.30 | $8.0M | Indirect | Jul 2, 2019 (0d) |
| Jun 20, 2019 | CHRS | ↓ Sell | 317,130 | $21.37 | $6.8M | Indirect | Jun 24, 2019 (4d) |
| May 22, 2019 | CHRS | ↓ Sell | 257,870 | $20.69 | $5.3M | Indirect | May 24, 2019 (2d) |
| May 13, 2019 | NXTC | ↑ Buy | 400,000 | $15.00 | $6.0M | Direct | May 15, 2019 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RAPP insiders
Open-market trades in the last 12 months
Ramiro Sanchez
Insider
1 buy
Oct 23, 2026
Steven M Paul
Insider
1 buy
Oct 22, 2026
Paul M Silva
Insider
1 buy
Oct 22, 2026
John Maraganore
Insider
1 buy
Oct 22, 2026
Wendy B. Young
Insider
1 buy
Oct 22, 2026
Troy A. Ignelzi
Chief Financial Officer
1 buy
Oct 21, 2026
Abraham Ceesay
Chief Executive Officer
11 sales
Oct 21, 2026
Cheryl Gault
Chief Operating Officer
5 sales
Sep 30, 2026
About James Healy's insider trades
James Healy is a director at Rapport Therapeutics (RAPP). Since Feb 23, 2006, James has reported 65 open-market purchases worth $282.1M and 29 sales worth $174.8M on SEC Form 4. In the last 12 months: 4 buys ($20.4M).
Their filings also include grants and awards (84 filings), conversions (33 filings), other transactions (19 filings), option exercises (18 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RAPP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.